van Lennep JE Roeters, Meijer E, Klumper FJ, Middeldorp JM, Bloemenkamp KW, Middeldorp S. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost 2011;9:473-80.Roeters van Lennep JE, Meijer E et al (2011) Prophylaxis with...
Low-Molecular-Weight Heparin Prophylaxis Dosing: Is Weight an Issue? Objective. To evaluate the pharmacokinetic, safety Yu-Yu,Kwee,Molly,... - 《Journal of Pharmacy Technology Jpt Official Publication of the Association of Pharmacy Technicians》 被引量: 0发表: 2016年 Low-Molecular-Weight Heparin ...
Heparin and Low-Molecular- Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Jack Hirsh, MD, FCCP, Chair; Theodore E. Warkentin, MD; Stephen G. Shaughnessy, PhD; Sonia S. Anand, MD; Jonathan L. Halperin, MD; Robert Raschke, MD, MS; Christopher...
While the secondary end points were: dose and indication validity for prophylaxis, VTE and bleeding risk assessments, adverse drug events (ADE) other than bleeding, appropriate monitoring when on low molecular weight heparin (LMWH) and the presence of contraindication at the time of prescribing LMWH...
LMWH has a greater bioavailability and appears to be as effective as unfractionated heparin for both treatment and prophylaxis of DVT; this is especially so in the outpatient setting. LMWH has resulted in shorter hospitalizations and reduced incidence of major bleeding complications. ...
Low-molecular weight heparin prophylaxis should not be recommended even in highly selected patients with solid cancer receiving outpatient chemotherapy. Oo TH. Low-molecular weight heparin prophy- laxis should not be recommended even in highly selected patients with solid cancer re- ceiving outpatient ...
Few attempts have been made to examine the feasibility of safely administering low-molecular-weight-heparins (LMWHs) in the presence of concurrent thrombocytopenia. We retrospectively investigated the safety of low-dose LMWH in BMT patients, a population at risk of bleeding. In total, 26 patients...
Low-molecular-weight heparins (LMWH) are a class of drugs used for treatment of patients with thrombosis, or blood clots, and as prophylaxis for those who are at risk of thrombosis. They are injectable drugs, usually given sub-cutaneously. Enoxaparin, dalteparin and nadroparin are all examples...
Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder The prospective evaluation of the effect of thromboprophylaxis in women with one unexplained pregnancy loss from the 10th week of amenorrhea was performed... JC Gris,E Mercier...
Abstract. In a randomized prospective trial, the efficacy of low molecular weight heparin (LMWH) (Fragmin®) and dextran 70 (Macrodex®) in preventing deep v